Cite
HARVARD Citation
Fangusaro, J. et al. (2021). A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro-oncology. 23 (10), pp. 1777-1788. [Online].